The city of San Antonio, Texas, currently has 15 active clinical trials seeking participants for Healthy research studies.
A Study to Assess the Drug Levels of Repotrectinib in Healthy Participants and Participants With Moderate and Severe Hepatic Impairment
Recruiting
The purpose of this study is to assess the drug levels of a single oral dose of repotrectinib in participants with moderate and severe HI, and in healthy matched control participants with normal hepatic function.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
06/12/2024
Locations: Local Institution - 0004, San Antonio, Texas +1 locations
Conditions: Hepatic Impairment, Healthy Volunteers
A Study of LY3437943 in Participants With Impaired and Normal Liver Function
Recruiting
The main purpose of this study is to measure how much of LY3437943 gets into the bloodstream and how long it takes the body to eliminate it in participants with mild, moderate and severe impaired liver function compared to healthy participants with normal liver function. The safety and tolerability of LY3437943 will also be evaluated. The study may last up to 9 weeks for each participant including the screening period.
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
05/30/2024
Locations: American Research Corporation at Texas Liver Institute, San Antonio, Texas +1 locations
Conditions: Healthy, Hepatic Insufficiency
Deliver-EE: Evaluating Effects of Meal Delivery
Recruiting
This study will randomly assign 2,300 older adults on waiting lists at nine Meals on Wheels programs in Florida, Texas, North Carolina, South Carolina, and California into two groups who will receive: (a) daily delivery of meals, five days a week or (b) a shipment of 10 frozen meals, every two weeks. Researchers will examine participants' Medicare claims to understand if differences in healthcare utilization occur between the two groups within six months after they start receiving meals. Researc... Read More
Gender:
All
Ages:
66 years and above
Trial Updated:
05/29/2024
Locations: Meals on Wheels San Antonio, San Antonio, Texas
Conditions: Healthy
A Study of LY3971297 in Healthy Participants and Participants With Obesity and Hypertension
Recruiting
The purpose of this study is to measure side effects of LY3971297 injection administered under the skin in healthy participants and obese participants with high blood pressure (BP). Blood tests will be performed to check how much LY3971297 gets into the bloodstream and how long it takes the body to eliminate it. This is a 5-part study. The study duration will be approximately 60 days for Part A and approximately 90 days for Parts B, C, D, and E.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
05/29/2024
Locations: ICON Early Phase Services, San Antonio, Texas
Conditions: Healthy, Obesity, Hypertension
A Drug-Drug Interaction (DDI) Study of Orforglipron With Carbamazepine in Healthy Participants
Recruiting
The main purpose of this study is to assess the effect of carbamazepine on the amount of orforglipron in the bloodstream and how long it takes the body to get rid of orforglipron when given orally in healthy study participants. The safety and tolerability of orforglipron and carbamazepine when given separately or together will also be evaluated. The study may last up to approximately 77 days for each participant.
Gender:
All
Ages:
Between 21 years and 70 years
Trial Updated:
05/29/2024
Locations: ICON Early Phase Services, San Antonio, Texas
Conditions: Healthy
A Study to Assess LY4100511 (DC-853) in Healthy Adult Participants
Recruiting
The main purpose of this study is to assess the effect of multiple doses of itraconazole, fluconazole, and carbamazepine on single dose pharmacokinetic of LY4100511 (DICE-853) in healthy participants. The study will also evaluate the safety and tolerability of LY4100511 (DICE-853) with itraconazole, fluconazole, and carbamazepine.
Gender:
All
Ages:
Between 18 years and 55 years
Trial Updated:
05/09/2024
Locations: ICON San Antonio Clinical Research Unit, San Antonio, Texas
Conditions: Healthy
A Study to Test How Avenciguat (BI 685509) is Taken up in the Body of People With and Without Liver Problems
Recruiting
This study is open to people with and without severe liver problems. People can join the study if they are 18 to 80 years of age and have a body mass index (BMI) between 18.5 and 42 kg/m2. Avenciguat (BI 685509) is a medicine that is being developed to treat high blood pressure in the portal vein (main vessel going to the liver). The purpose of this study is to find out whether having liver problems influences how Avenciguat (BI 685509) is taken up in the body. All participants take Avenciguat... Read More
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
04/30/2024
Locations: American Research Corporation at the Texas Liver Institute, San Antonio, Texas
Conditions: Healthy, Liver Diseases
A Study to Investigate the Safety and Tolerability of LY3938577 in Healthy Participants and Participants With Type 2 Diabetes Mellitus
Recruiting
The main purpose of this study is to assess the safety and tolerability of a single dose of LY3938577 in healthy participants and participants with Type 2 Diabetes Mellitus (T2DM) (Part A) and multiple doses of LY3938577 in participants with T2DM (Part B). The study will last approximately 6 weeks for Part A and approximately 10 weeks for Part B respectively.
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
04/18/2024
Locations: Endeavor Clinical Trials, San Antonio, Texas
Conditions: Healthy, Type 2 Diabetes Mellitus
A Study to Assess the Relative Bioavailability of 5 mg Mavacamten Opened Capsule Administered Via Nasogastric Tube Compared to Intact Oral 5 mg Mavacamten in Healthy Participants
Recruiting
The purpose of this study to assess the relative bioavailability of 5 mg Mavacamten opened capsule administered via nasogastric tube compared to intact oral 5 mg Mavacamten in healthy volunteers.
Gender:
All
Ages:
Between 18 years and 60 years
Trial Updated:
02/29/2024
Locations: Worldwide Clinical Trials, San Antonio, Texas
Conditions: Healthy Volunteers
A Study of LY3502970 in Participants With Impaired and Normal Liver Function
Recruiting
The main purpose of this study is to measure how much of LY3502970 gets into the bloodstream and how long it takes the body to eliminate it in participants with mild, moderate and severe impaired liver function compared to participants with normal liver function. The safety and tolerability of LY3502970 will also be evaluated. The study may last up to 6 weeks for each participant including the screening period.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
01/29/2024
Locations: Texas Liver Institute, San Antonio, Texas +1 locations
Conditions: Healthy, Hepatic Insufficiency
Study of CBP-4888 in Healthy, Non-Pregnant Female Subjects
Recruiting
This is a Phase I, first-in-human, single-center, randomized, double-blind, placebo-controlled, single ascending dose study to evaluate the safety, tolerability, and PK of ascending doses of CBP-4888.
Gender:
Female
Ages:
Between 18 years and 50 years
Trial Updated:
01/23/2024
Locations: Comanche Biopharma Clinical Research Site #1, San Antonio, Texas
Conditions: Healthy Volunteer Study
PK and Safety in Participants Taking Obicetrapib With Moderate Hepatic Impairment Relative to Normal Hepatic Function
Recruiting
To investigate the safety and pharmacokinetics in patients with moderate hepatic impairment compared to healthy participants after a single oral dose of obicetrapib (10 mg).
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
01/20/2024
Locations: The American Research Corporation, San Antonio, Texas
Conditions: Hepatic Impairment, Healthy